Recent Updates
Recently added Catalysts
INO

Investors: Bernie Hertel, Inovio Biomedical, 858-410-3101 Media: Ron Trahan, Ronald Trahan Associates Inc., 508-359-4005, x108 Inovio Biomedical and VGX Pharmaceuticals to High

Thursday, December 4, 2008 3 min read
Key Takeaway: CONTACTS Investors: Bernie Hertel, Inovio Biomedical, 858-410-3101 Media: Ron Trahan, Ronald Trahan Associates Inc., 508-359-4005, x108 Inovio Biomedical and VGX Pharmaceuticals to Highlight Electroporation-Delivered DNA Vaccines at International DNA Vaccines Conference SA

Full Press Release Details

CONTACTS
Investors: Bernie Hertel, Inovio Biomedical, 858-410-3101
Media: Ron Trahan, Ronald Trahan Associates Inc., 508-359-4005, x108
Inovio Biomedical and VGX
Pharmaceuticals to Highlight
Electroporation-Delivered
DNA Vaccines at International
DNA Vaccines Conference

SAN DIEGO, Dec. 4, 2008 Inovio Biomedical Corporation (INO: NYSE Alternext, formerly AMEX) and VGX Pharmaceuticals announced today they will make multiple presentations concerning electroporation-delivered DNA vaccines in the fight against cancer, HIV and other infectious diseases at DNA Vaccines 2008 , a conference hosted by The International Society of DNA Vaccines in Las Vegas, NV, at The Tropicana Hotel, December 9 - 11. Inovio and VGX, co-sponsors of the event, are advancing a powerful delivery method, electroporation, to enhance the potency of DNA-based immunotherapies and vaccines against infectious diseases and cancers.

Researchers and executive management from Inovio
and VGX, as well as their collaborators, will be making the following
presentations regarding electroporation-delivered DNA vaccines:

HCV Vaccines ( State of the Art Sessions)

Matti Sallberg, Karolinska Institute
Approaches (State of the Art Sessions)
David Weiner, DNA Vaccines 2008
University of Pennsylvania

4:00 p.m.

LifeTide SW5 - From Basic Research to Commercial Product

(Electroporation Focused Session)

Ruxandra Draghia-Akli, VGX Pharmaceuticals

Wednesday December 10

DNA Vaccines Delivered by
Electroporation Challenges Related to Humans
(Electroporation Focused Session)
Iacob Mathiesen, Inovio

Wednesday, December 10

Corporate - Roundtable What s Next for DNA Vaccines? (Electroporation Focused Session)

Moderator : John Sterling, Editor-In-Chief, Genetic Engineering News J. Joseph Kim, VGX Pharmaceuticals Avtar Dhillon, Inovio Biomedical Wednesday, December 10

Manufacturing a High Concentration Multi-Component DNA Vaccine

(Production Technology Session)

Robert J. Juba, VGXI, Inc.

Thursday, December 11

Approaches to Melanoma ( T-Cell Immunology Session)

Richard Heller, Old Dominion University

Thursday, December 11

11:20 a.m.

DNA Vaccines 2008 Highlights: Clinical Summaries C. Jo White, VGX Pharmaceuticals

Thursday, December 11

Inovio, VGX and collaborators will also present
multiple posters at the conference, covering the topics of DNA vaccines for
influenza, smallpox, and cancer as well as optimized electroporation methods
and VGX announced a definitive merger agreement on July 7, 2008.
About VGX Pharmaceuticals
VGX Pharmaceuticals is a biopharmaceutical company
engaged in the discovery and development of novel vaccines and therapies for
major infectious diseases and cancers. VGX s clinical development programs
include PENNVAX -B, a DNA vaccine for the prevention of HIV in Phase I clinical
trials; VGX-1027, a small molecule drug for inflammatory diseases in Phase I
clinical trials; VGX-3100, a DNA therapeutic vaccine for cervical cancer in
Phase I clinical trials; and the CELLECTRA electroporator, a DNA delivery
device in Phase I clinical trials. In
addition, VGX has filed INDs for VGX-3200, a novel DNA therapy that utilizes
GHRH for the treatment of cancer cachexia and anemia and for VGX-3400, a DNA
preventative vaccine for avian influenza. VGX has established a
vertically-integrated DNA Vaccines and Therapies Platform with extensive
capabilities including SynCon DNA-based product candidates, the CELLECTRA
delivery device, and access to efficient cGMP plasmid manufacturing. Vertical control
over key aspects of product development has enabled VGX to consistently develop
multiple product candidates, from bench-to-IND filing, within one year. The
product candidates and technology programs are protected by VGX s extensive
global intellectual property portfolio. More information about VGX can
be found at www.vgxp.com.
About Inovio Biomedical
Inovio Biomedical is focused on developing DNA
vaccines for cancers and infectious diseases using its novel method for DNA
delivery electroporation which uses brief, controlled electrical pulses to
increase cellular uptake of useful biopharmaceuticals. Initial human data has
shown that Inovio s electroporation-based DNA delivery technology can
significantly increase gene expression and immune responses from DNA vaccines.
Immunotherapy partners include Merck, Wyeth, Vical, University of Southampton,
Moffitt Cancer Center, the U.S. Army, National Cancer Institute, and
International Aids Vaccine Initiative. Inovio s technology is protected by an
extensive patent portfolio covering in vivo
electroporation. More information is available at www.inovio.com.

This press release contains certain forward-looking statements relating to Inovio s and VGX s plans to develop DNA-based immunotherapies and vaccines and electroporation drug and gene delivery technology. Actual events or results may differ from the companies expectations as a result of a number of factors, including the uncertainties inherent in clinical trials and product development programs (including, but not limited to, the fact that pre-clinical and clinical results referenced in this release or in the presentations and posters to be presented at the conference may not be indicative of results achievable in other trials or for other indications and that results from one study may not necessarily be reflected or supported by the results of other similar studies), the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of the companies technologies, including electroporation as a delivery mechanism, the availability or potential availability of alternative therapies or treatments for the conditions targeted by Inovio, VGX or their collaborators, including alternatives that may be more efficacious or cost-effective than any therapy or treatment that Inovio, VGX or their collaborators hope to develop, evaluation of potential opportunities, issues involving patents and whether they or licenses to them will provide either company with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether the company in question can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of Inovio s and VGX s technology by potential corporate or other partners or collaborators, capital market conditions, and other factors set forth in Inovio s Annual Report on Form 10-K for the year ended December 31, 2007, Inovio s 10-Q for the nine months ended September 30, 2008 and other regulatory filings made by either company from time to time. There can be no assurance that any product in the Inovio or VGX product pipeline will be successfully developed or manufactured, that final results of clinical studies will be supportive of regulatory approvals required to market licensed products, or that any of the forward-looking information provided herein will be proved accurate.

Tags: INO Viatris Investor Conferences Healthcare investor conferences healthcare conferences UBS Global Healthcare
Last updated: Dec 4, 2008